



## Pricing & Reimbursement/Market Access Working Group Agenda

- 1 **Welcome / Meeting agenda**
- 2 **Sweden: Innovative payment models for ATMPs – Which are the obstacles for implementation?** (Douglas Lundin, TLV)
- 3 **Germany: “Medical Research Act” draft bill – confidential pricing and impact on reimbursement** (Thomas Ecker, Ecker + Ecker)
- 4 **Update on WHO Europe’s Access to Novel Medicines Platform**
  - Working Group 1 – Transparency
  - Working Group 2 – Solidarity (Thomas Grub, Medac)
  - Working Group 3 – Sustainability (Thomas Bols, PTC & Fabian Schmidt, Recordati)
- 5 **Poland: What does the vast reimbursement reform actually mean for the pharmaceutical industry?** (Anna Wiktorow-Bojska, WKB Lawyers)
- 6 **Further country updates**
- 7 **AOB / End of meeting**